PL3920890T3 - Doustna tabletka kannabinoidowa - Google Patents

Doustna tabletka kannabinoidowa

Info

Publication number
PL3920890T3
PL3920890T3 PL20726699.0T PL20726699T PL3920890T3 PL 3920890 T3 PL3920890 T3 PL 3920890T3 PL 20726699 T PL20726699 T PL 20726699T PL 3920890 T3 PL3920890 T3 PL 3920890T3
Authority
PL
Poland
Prior art keywords
oral cannabinoid
tablet
cannabinoid tablet
oral
cannabinoid
Prior art date
Application number
PL20726699.0T
Other languages
English (en)
Inventor
Heidi Ziegler Bruun
Dorte Schackinger BOESEN
Ane Eriksen
Helle Wittorff
Original Assignee
Nordiccan A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3040513A external-priority patent/CA3040513C/en
Priority claimed from US16/386,477 external-priority patent/US10925853B2/en
Application filed by Nordiccan A/S filed Critical Nordiccan A/S
Publication of PL3920890T3 publication Critical patent/PL3920890T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20726699.0T 2019-04-17 2020-04-17 Doustna tabletka kannabinoidowa PL3920890T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA3040513A CA3040513C (en) 2019-04-17 2019-04-17 An oral cannabinoid tablet
US16/386,477 US10925853B2 (en) 2019-04-17 2019-04-17 Oral cannabinoid tablet
PCT/DK2020/050100 WO2020211913A1 (en) 2019-04-17 2020-04-17 An oral cannabinoid tablet

Publications (1)

Publication Number Publication Date
PL3920890T3 true PL3920890T3 (pl) 2024-03-18

Family

ID=70775241

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20726699.0T PL3920890T3 (pl) 2019-04-17 2020-04-17 Doustna tabletka kannabinoidowa

Country Status (8)

Country Link
EP (2) EP4289423A3 (pl)
CN (1) CN113710235B (pl)
AU (1) AU2020259627B2 (pl)
DK (1) DK3920890T3 (pl)
ES (1) ES2966539T3 (pl)
FI (1) FI3920890T3 (pl)
PL (1) PL3920890T3 (pl)
WO (1) WO2020211913A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096894B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet for induced saliva generation
US11633351B2 (en) * 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
JP2024512417A (ja) * 2021-03-12 2024-03-19 ニコベンチャーズ トレーディング リミテッド 自己乳化系を含む経口製品
US20240008514A1 (en) 2022-07-05 2024-01-11 Fertin Pharma A/S Cannabinoid Lipid Premixture
JP2025520956A (ja) * 2022-07-05 2025-07-03 フェルティン ファルマ アー/エス カンナビノイド脂質予混合物
US20260224493A1 (en) * 2023-01-27 2026-08-06 Fertin Pharma A/S An Adhesive Oral Disc For Sustained Release Of Cannabinoids
US20260224480A1 (en) * 2023-01-27 2026-08-06 Philip Morris Products S.A. System for oral delivery of an active ingredient
WO2025032115A1 (en) * 2023-08-08 2025-02-13 Avextra Portugal Sa Cannabinoid granule composition
DK202330231A1 (en) * 2023-09-27 2025-04-10 Fertin Pharma As Cannabidiol for alleviating xerostomia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2609912A1 (en) * 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Pharmaceutical combination of fingolimod and nabiximols
CA2992923C (en) * 2014-07-21 2021-06-29 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal and sublingual administration of cannabinoids
US10765658B2 (en) * 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
CA3052564A1 (en) * 2017-02-05 2018-08-09 CannTab Therapeutics Limited Flash-melt cannabinoid formulations
US10772837B2 (en) * 2017-03-16 2020-09-15 CannTab Therapeutics, Ltd Modified release multi-layer tablet cannabinoid formulations

Also Published As

Publication number Publication date
CN113710235B (zh) 2024-03-29
EP4289423A3 (en) 2024-02-21
AU2020259627B2 (en) 2023-09-21
EP3920890A1 (en) 2021-12-15
FI3920890T3 (fi) 2023-11-30
DK3920890T3 (da) 2023-11-27
ES2966539T3 (es) 2024-04-22
AU2020259627A1 (en) 2021-10-28
CN113710235A (zh) 2021-11-26
EP3920890B1 (en) 2023-11-01
WO2020211913A1 (en) 2020-10-22
EP4289423A2 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
IL288423A (en) Cannabinoid formulations
EP3994692C0 (en) BINARY COMPUTING CELL IN MEMORY
DK3920890T3 (da) Oral cannabinoid-tablet
IL292161A (en) New methylquinazolinone derivatives
DK3935068T3 (da) Abirateron-prodrugs
EP4007967A4 (en) Multiply-accumulate unit
EP3997095C0 (en) CANNABINOID DERIVATIVES
EP3930851A4 (en) COMBINATION THERAPIES
EP3919491C0 (en) AKT INHIBITOR
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
IL288173A (en) Sonosensitization
EP3967649C0 (en) LIPID NANOPARTICLE
EP3998174A4 (en) SEAT
EP4065549A4 (en) Cannabinoid derivatives
EP3973348A4 (en) HEAD MOUNT DISPLAYS
EP3912517C0 (en) FRAME
EP3957391C0 (en) AGITATOR
EP3975220A4 (en) Display panel
EP3962498A4 (en) Combination therapies
EP4032513A4 (en) MOUTHPIECE
EP4005489A4 (en) Stethoscope
EP3965638C0 (en) VAGINAL SPECULUM
DK3738452T3 (da) Fordamper
EP3682831C0 (en) CRYOGENIC APPLICATOR
PL3965739T3 (pl) Postacie dawkowane będące tabletkami oleilofosfocholiny